1Polly E. Anticancer Drug- Induced Kidney Disorders. Drug Safety,2001,24(1):19. 被引量：1
2Cantrell JE, Phillips TM, Schein PS. Carcinoma - associated hemolytic- uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol, 1985,3:723. 被引量：1
4Hanna WT, Krauss S, Regester RF, et al. Renal disease after mitomyein C therapy, Cancer, 1981,48:2 583. 被引量：1
5Lesesne JB, Rothschild N, Erickson B, et al. Cancer - associated hemolytic - uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol, 1989,7:781. 被引量：1
6Liu K, Mittelman A, Sproul EE, et al, Renal toxicity in man treated with mitomycin C. Cancer, 1971,5:1 314. 被引量：1
8Jolivet J, Giroux L, Laurin S, et al. Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edems: a chemotherapy -induced syndrome. Cancer Treat Rep, 1983,67:429. 被引量：1
9Rabadi SJ, Khandeker JD, Miller HJ. Mitomycin- induced hemolytic uremic syndrome: case presentation and review of the literature. Cancer Treat Rep, 1982,66:1 244. 被引量：1
10Sutton TA, Molitoris BA. Mechanisms of cellular injury in ischemic acute renal failure. Semin Nephrol, 1998,18:490. 被引量：1
6Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome: a review of 37 patients with Burkitt' s lymphoma[J].Am J Med, 1980, 68(4): 486. 被引量：1
7Relling MV, Fariclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity[J]. J Clin Oncol, 1994,12 (8) : 1 667. 被引量：1
